Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19240239 | HETEROARYL COMPOUNDS, SOLID FORMS, PREPARATION METHODS AND USES THEREOF | June 2025 | February 2026 | Allow | 8 | 1 | 1 | Yes | No |
| 19223498 | SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF | May 2025 | January 2026 | Allow | 8 | 2 | 1 | Yes | No |
| 19183531 | TARGETED PROTEIN DEGRADATION | April 2025 | July 2025 | Allow | 2 | 0 | 1 | No | No |
| 19058521 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | February 2025 | September 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18975881 | SELECTIVE ANGIOTENSIN II COMPOUNDS | December 2024 | July 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18917653 | NLRP3 INFLAMMASOME INHIBITORS | October 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18804311 | NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVES | August 2024 | January 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18777202 | PARP1 INHIBITORS AND USES THEREOF | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18770015 | PHTHALAZINONE BASED MODULATORS FOR THE TREATMENT OF DISEASE | July 2024 | July 2025 | Allow | 12 | 2 | 2 | Yes | No |
| 18754527 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | June 2024 | September 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18736710 | 5-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTS | June 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18661628 | POLYDENTATE ORGANIC LIGAND, METALLO-SUPRAMOLECULAR POLYMER, POLYMER FILM AND PREPARATION METHOD THEREOF | May 2024 | September 2025 | Allow | 17 | 1 | 1 | No | No |
| 18623808 | 5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | April 2024 | June 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18623544 | 5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | April 2024 | September 2024 | Allow | 5 | 1 | 0 | No | No |
| 18618824 | 5-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTS | March 2024 | November 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18692791 | AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR | March 2024 | March 2025 | Abandon | 13 | 2 | 1 | Yes | No |
| 18595801 | Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease | March 2024 | January 2026 | Allow | 23 | 1 | 1 | No | No |
| 18688683 | THERAPEUTIC COCRYSTALS OF 3-{[5-(AZETIDINE-1-YLCARBONYL)PYRAZIN-2-YL]OXY}-5-{[(1S)-1-METHYL-2-(METHYLOXY)ETHYL]OXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDE | March 2024 | March 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18590749 | Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System | February 2024 | January 2026 | Allow | 23 | 1 | 1 | No | No |
| 18586620 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | February 2024 | August 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18443925 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | February 2024 | August 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18434601 | 7-(4-((5-(2-CHLOROBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUND | February 2024 | April 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18430400 | 2-[(1H-BENZIMIDAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18428046 | SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS | January 2024 | October 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18422258 | INHIBITORS OF RET | January 2024 | February 2026 | Allow | 24 | 1 | 1 | No | No |
| 18393915 | SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTS | December 2023 | August 2024 | Allow | 7 | 1 | 1 | No | No |
| 18391047 | PYRAZOLOPYRIMIDINE COMPOUNDS | December 2023 | June 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18536912 | PYRROLO[3,2-C]QUINOLINE-2,3-DIONE COMPOUNDS AS CK2 INHIBITORS | December 2023 | April 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18533073 | PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORS | December 2023 | March 2024 | Allow | 3 | 1 | 1 | No | No |
| 18532293 | PYRAZINE COMPOUND | December 2023 | May 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18533067 | PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORS | December 2023 | March 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18388734 | 5-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5- d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTS | November 2023 | September 2024 | Abandon | 11 | 1 | 1 | No | No |
| 18386545 | 5-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 1 | 1 | No | No |
| 18384080 | PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS | October 2023 | August 2025 | Allow | 22 | 0 | 1 | Yes | No |
| 18382805 | 2-[(1H-BENZIMIDAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | August 2024 | Abandon | 9 | 1 | 1 | No | No |
| 18491686 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | October 2023 | September 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18377125 | ASK1 INHIBITING AGENTS | October 2023 | May 2025 | Allow | 19 | 1 | 1 | No | No |
| 18372115 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | September 2023 | April 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18368362 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | September 2023 | April 2025 | Allow | 19 | 1 | 1 | No | No |
| 18244644 | PYRROLO[3,4-B]QUINOLINE COMPOUNDS AS ANTIBACTERIAL AGENTS | September 2023 | January 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18244281 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | September 2023 | November 2023 | Allow | 3 | 1 | 0 | No | No |
| 18242753 | PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORS | September 2023 | February 2024 | Allow | 5 | 1 | 1 | No | No |
| 18241383 | 7-(4-((5-(BENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | September 2023 | February 2024 | Allow | 5 | 2 | 1 | Yes | No |
| 18240853 | HDAC INHIBITOR SOLID STATE FORMS | August 2023 | August 2024 | Allow | 11 | 0 | 0 | No | No |
| 18455865 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | August 2023 | June 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18236458 | SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTS | August 2023 | November 2023 | Allow | 3 | 0 | 1 | Yes | No |
| 18234973 | 5-(3-SUBSTITUTED PHENYL)-PYRIMIDO[4,5-d]PYRIMIDINE-2,4,7(1H,3H,8H)-TRIONE DERIVATIVES AS ANTICANCER AGENTS | August 2023 | January 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18232012 | 5-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTS | August 2023 | September 2024 | Abandon | 13 | 2 | 1 | No | No |
| 18353410 | INHIBITORS OF NLRP3 INFLAMMASOME | July 2023 | August 2025 | Allow | 25 | 2 | 1 | No | No |
| 18353370 | INHIBITORS OF NLRP3 INFLAMMASOME | July 2023 | May 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18352078 | MK2 INHIBITORS AND USES THEREOF | July 2023 | November 2023 | Allow | 4 | 1 | 0 | No | No |
| 18333262 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | June 2023 | June 2025 | Allow | 24 | 1 | 1 | No | No |
| 18333459 | PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATOR | June 2023 | March 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18331758 | PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOF | June 2023 | November 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 18266156 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | June 2023 | March 2026 | Abandon | 33 | 0 | 1 | No | No |
| 18327775 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | June 2023 | September 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18323939 | INHIBITORS OF NLRP3 INFLAMMASOME | May 2023 | January 2026 | Allow | 32 | 3 | 1 | No | No |
| 18196601 | PYRIDAZINONES AS PARP7 INHIBITORS | May 2023 | August 2025 | Allow | 27 | 1 | 1 | No | No |
| 18143975 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | May 2023 | July 2025 | Allow | 26 | 2 | 1 | No | No |
| 18310943 | MK2 INHIBITORS AND USES THEREOF | May 2023 | September 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 18310463 | CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOF | May 2023 | May 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18309164 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | April 2023 | February 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18309031 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | April 2023 | August 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 18306236 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | April 2023 | May 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18133666 | CRYSTALLINE SUBSTITUTED PYRAZINES AS PGI2 RECEPTOR AGONISTS | April 2023 | July 2024 | Allow | 15 | 0 | 1 | No | No |
| 18126646 | ENZYME INHIBITORS | March 2023 | October 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18125449 | PYRROLO[3,4-B]QUINOLINE COMPOUNDS AS ANTIBACTERIAL AGENTS | March 2023 | August 2023 | Allow | 5 | 1 | 1 | Yes | No |
| 18027870 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | March 2023 | February 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18184766 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | March 2023 | May 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18121318 | Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous System | March 2023 | December 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18183039 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE | March 2023 | January 2026 | Abandon | 34 | 3 | 0 | No | No |
| 18120806 | CDK INHIBITORS | March 2023 | October 2025 | Allow | 32 | 2 | 0 | No | No |
| 18179841 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | March 2023 | October 2023 | Allow | 7 | 2 | 1 | Yes | No |
| 18117847 | COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIES | March 2023 | March 2025 | Allow | 25 | 2 | 1 | No | No |
| 18176107 | Porphyrin Compounds and Compositions Useful for Treating Cancer | February 2023 | June 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18115314 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | February 2023 | September 2023 | Allow | 6 | 1 | 1 | No | No |
| 18174983 | Organic Electroluminescent Element And Novel Iridium Complex | February 2023 | February 2026 | Allow | 35 | 2 | 1 | Yes | No |
| 18110626 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | February 2023 | September 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18105427 | Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host Disease | February 2023 | December 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 18104655 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | February 2023 | April 2025 | Allow | 27 | 1 | 1 | No | No |
| 18162127 | FGFR INHIBITORS AND METHODS OF USE THEREOF | January 2023 | May 2023 | Allow | 3 | 0 | 0 | No | No |
| 18102359 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | January 2023 | October 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18160240 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | January 2023 | May 2025 | Allow | 27 | 2 | 1 | Yes | No |
| 18099770 | PARP1 INHIBITORS AND USES THEREOF | January 2023 | November 2023 | Allow | 9 | 2 | 1 | Yes | No |
| 18096397 | INHIBITOR OF INDOLEAMINE 2,3-DIOXYGENASE-1 AND METHODS OF MANUFACTURE AND USE THEREOF | January 2023 | August 2025 | Abandon | 31 | 2 | 1 | No | No |
| 18151688 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | January 2023 | April 2025 | Allow | 27 | 1 | 1 | No | No |
| 18149740 | CLEAVABLE AGENTS | January 2023 | September 2025 | Abandon | 32 | 1 | 1 | No | No |
| 18003849 | ORGANIC COMPOUND AND ELECTRONIC DEVICE AND ELECTRONIC APPARATUS THEREOF | December 2022 | June 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18081951 | Methods for the Prevention and Treatment of Hearing Loss | December 2022 | February 2026 | Allow | 38 | 4 | 1 | Yes | No |
| 18066507 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | December 2022 | April 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18080566 | HDAC INHIBITOR SOLID STATE FORMS | December 2022 | August 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 18079617 | PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | December 2022 | January 2024 | Allow | 13 | 2 | 1 | No | No |
| 18075513 | SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTS | December 2022 | July 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 18075853 | NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS | December 2022 | March 2025 | Allow | 28 | 2 | 1 | Yes | No |
| 18075270 | PTERIDINONE COMPOUNDS AND USES THEREOF | December 2022 | January 2025 | Allow | 26 | 1 | 0 | No | No |
| 17980186 | COMPOSITIONS RELATED TO SUBSTITUTED PYRAZINES AS CTPS INHIBITORS | November 2022 | May 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17968408 | Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 Imhibitors | October 2022 | January 2025 | Allow | 27 | 1 | 1 | No | No |
| 17965843 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | October 2022 | March 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 17957584 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | September 2022 | August 2023 | Abandon | 11 | 1 | 1 | No | No |
| 17946236 | CRYSTALLINE FORMS OF PIPERAZINE-1,4-DIYLBIS((6-(1H-BENZO[D]IMIDAZO-2-YL)PYRIDIN-2YL)METHANONE) | September 2022 | February 2025 | Allow | 29 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCDOWELL, BRIAN E.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MCDOWELL, BRIAN E works in Art Unit 1624 and has examined 1,393 patent applications in our dataset. With an allowance rate of 66.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner MCDOWELL, BRIAN E's allowance rate of 66.1% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MCDOWELL, BRIAN E receive 1.55 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by MCDOWELL, BRIAN E is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +36.0% benefit to allowance rate for applications examined by MCDOWELL, BRIAN E. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 50% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 35.6% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 14.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 86.8% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 78.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 5.6% of allowed cases (in the 87% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.2% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.